<DOC>
	<DOCNO>NCT00002191</DOCNO>
	<brief_summary>To evaluate efficacy ( stool frequency ) safety ( adverse experience ) albendazole , administer 28 day , compare placebo 62 day open-label fashion , treat intestinal microsporidiosis HIV-positive patient . To assess effect albendazole stool volume , weight gain , microsporidial count small bowel biopsy , relationship microsporidial count stool stool frequency volume . To correlate microsporidial count clinical course microsporidiosis .</brief_summary>
	<brief_title>A Double-Blind , Placebo-Controlled Trial Albendazole HIV-Positive Patients With Intestinal Microsporidiosis</brief_title>
	<detailed_description>In double-blind portion study , patient receive albendazole placebo 28 day ; open-label portion study , patient receive albendazole 62 day .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Protozoan Infections</mesh_term>
	<mesh_term>Microsporidiosis</mesh_term>
	<mesh_term>Albendazole</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : If coincident enteric pathogen eradicable ( i.e. , Mycobacterium avium complex ) detect , treat appropriately patient must stable regimen therapy least two week . Allowed : Patients take antidiarrheal medication must stable regimen least seven day prior randomization . Patients take concomitant medication , include antiretrovirals , must stable regimen two week prior randomization . Patients must : HIV positive status . Written documentation ( example , patient 's chart ) HIV diagnosis acceptable lieu repeat test . Confirmation Western blot necessary . Biopsyproven microsporidiosis fourth portion duodenum proximal jejunum within 90 day randomization . Average &gt; 3 liquid bowel movement per day 7 consecutive day immediately prior randomization , average volume &gt; 500 ml per day three consecutive day immediately prior randomization , document data collect daily diary . NOTE : Patients receive antidiarrheal therapy must meet criterion despite therapy . History average &gt; 3 liquid bowel movement per day three additional week immediately precede 7day period describe ( total four week ) , document patient 's chart . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Grade 4 neutropenia . Decompensated liver disease . Positive toxin analysis C. difficile . Positive microscopic examination Giardia lamblia , Entamoeba histolytica , Isospora belli . Positive culture Shigella , Salmonella , Yersinia Campylobacter . Positive fluorescent antibody test Cryptosporidium . Evidence CMV small bowel biopsy , flexible sigmoidoscopic colonoscopic biopsy within 90 day randomization . Any condition , opinion investigator , make patient unsuitable study entry . Patients follow prior condition exclude : Hypersensitivity albendazole . Prior Medication : Excluded : Use potential antiprotozoal drug , e.g. , mebendazole metronidazole , within one week prior enrollment . Receipt albendazole one month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1997</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Placebos</keyword>
	<keyword>Protozoan Infections</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Albendazole</keyword>
	<keyword>Microsporida</keyword>
	<keyword>Anthelmintics</keyword>
</DOC>